T-Cypher Bio

T-Cypher Bio is a pioneering force in biotechnology research, dedicated to unlocking an expansive target space to develop a robust pipeline of novel, TCR-based therapeutics. With a focus on transforming the treatment of immune-mediated diseases, T-Cypher Bio leverages proprietary platforms to gain unique insights into T cell-based immunity in both healthy and diseased states.

The company’s high-throughput, high-resolution profiling of the immune synapse enables precise mapping of the intracellular target space and detailed profiling of T cell specificity. These advanced platforms not only facilitate the creation of highly innovative drugs but also generate immune system datasets of unprecedented scale. This wealth of data supports cutting-edge computational modeling of T cell repertoires, poised to revolutionize the field of T cell immunology.

T-Cypher Bio is committed to building a comprehensive oncology pipeline. The company rigorously validates novel, shared, tumor-specific targets and identifies panels of rare, functionally-defined T cell clones. The unique TCRs identified form the foundation of a broad pipeline of potentially life-saving therapeutics for underserved solid tumor patients. Located in Oxford, GB, T-Cypher Bio is actively expanding its reach and impact in the biotechnology sector. We invite the management team at T-Cypher Bio to create a customized and exclusive company showcase and product listing on our platform to further amplify their innovative work.